Leidos Biomedical Research, Inc. (LBRI), a wholly owned subsidiary of Leidos, operates the Frederick National Laboratory for Cancer Research (FNLCR). FNLCR is a Federally Funded Research and Development Center (FFRDC) sponsored by the National Cancer Institute (NCI). It is the only FFRDC dedicated to biomedical research. Through its status as an FFRDC, FNLCR provides NCI and others with a unique national resource to accelerate the development and delivery of effective preventive, diagnostic, and therapeutic products for cancer and AIDS.
The breadth of FNLCR’s activities spans the research and development spectrum, including investigator-initiated, hypothesis-driven research into cancer and AIDS; advanced technology programs focused on genetics and genomics, proteins and proteomics, imaging, nanotechnology, bioinformatics, and laboratory animal sciences; clinical operations in support of NCI and National Institute of Allergy and Infectious Diseases (NIAID)-sponsored clinical trials, as well as NCI drug discovery and development efforts; and management and operations of biopharmaceutical development and manufacturing programs under current Good Manufacturing Practice conditions for NCI and NIAID. Administrative, procurement, financial, safety, and facilities support is provided to these R&D activities through state-of-the-art business processes. LBRI has approximately 1,900 employees and manages an annual operating budget of approximately $450M.
For more information about Leidos Biomedical Research Inc., please visit our webpage at www.leidosbiomed.com.
The Clinical Services Program's primary mission is to perform sequential studies of immune function in patients with cancer, AIDS, chronic granulomatous disease or other diseases associated with immunologic dysfunction, as well as to monitor viral load in patients with HIV.
We are seeking a highly motivated and talented individual with a strong background in tumor immunology to work on preclinical studies of evaluation of candidate cancer vaccines in preclinical development. These studies will include in vivo and in vitro evaluations of immunogenicity, tumorigenicity and vaccine efficacy testing using mouse models.
The Research Associate I will: 1) optimize and validate procedures and methodologies for assessment of immunogenicity and efficacy of different cancer vaccine candidates, 2) plan experiments and conduct testing, 3) with limited supervision, design and implement protocols, as well as troubleshoot assays and experiments independently, 4) evaluate, analyze and compile data, maintain databases, 5) be responsible for routine QC/QA procedures, ordering supplies, and maintaining equipment and inventories, 6) prepare reports and present data, and 7) remain current on literature and relevant laboratory techniques.
Work may involve the use of potentially hazardous chemical, biological, or radiological materials or may be located in areas where such materials are used.
Possession of a Bachelor’s degree from an accredited college/university according to the Council for Higher Education Accreditation (CHEA) in a field related to biomedical research or four (4) years equivalent experience in the appropriate field in lieu of degree.
Foreign degrees must be evaluated for U.S. equivalency
Minimum of two (2) years of related biomedical experience
Strong background in tumor immunology and vaccines
Experience in tissue culture, cell line maintenance, immunological/virological techniques, production of plasmids, Western-blot
Strong experience in ELISA, ELISPOT, Luminex assays, flow cytometry, immunohistochemistry
Proficient in molecular biology techniques
Ability to design and troubleshoot assays and experiments independently
Ability to evaluate and analyze experimental results
Ability to function independently
Experience with assay development
Familiarity with current scientific literature
MS in immunology, vaccinology, virology or molecular biology
Experience with project management
Experience in preclinical research of vaccines/biologics
Familiarity with regulatory and GMP, GCLP and GLP